Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Fate Therapeutics, Inc.
FATE
$1.36
Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $157,536,992.00
EPSttm : -1.15
finviz dynamic chart for FATE
Fate Therapeutics, Inc.
$1.36
3.44%
$0.045
FATE — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

8.95

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

-0.01

EPS Last/This Y

EPS This/Next Y

0.1

Price

1.32

Target Price

4.94

Analyst Recom

2

Performance Q

24.76

Upside

-1,241.2%

Beta

2.24

Ticker: FATE



17 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-17FATE1.1350.101.207579
2026-03-18FATE1.0550.100.457580
2026-03-19FATE1.080.101.677668
2026-03-20FATE1.110.100.047672
2026-03-23FATE1.160.100.046940
2026-03-24FATE1.140.100.086974
2026-03-25FATE1.220.104.006921
2026-03-26FATE1.2250.110.116958
2026-03-27FATE1.180.110.316981
2026-03-30FATE1.1350.110.016984
2026-03-31FATE1.20.110.297095
2026-04-01FATE1.2350.110.137099
2026-04-02FATE1.2150.110.007072
2026-04-06FATE1.1950.111.006915
2026-04-08FATE1.1850.1110.436923
2026-04-09FATE1.270.112.966929
2026-04-13FATE1.310.110.047098
DateSymbolLatestP/C OIP/C VolTotal OI
17 items Current Page1 of 1



19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-17FATE1.1313.7- -1.16
2026-03-18FATE1.0513.7- -1.16
2026-03-19FATE1.0813.7- -1.16
2026-03-20FATE1.1113.7- -1.16
2026-03-23FATE1.1613.7- -1.16
2026-03-24FATE1.1413.7- -1.16
2026-03-25FATE1.2213.7- -1.16
2026-03-26FATE1.2313.7- -1.16
2026-03-27FATE1.1813.7- -1.16
2026-03-30FATE1.1313.3- -1.15
2026-03-31FATE1.2113.3- -1.15
2026-04-01FATE1.2313.3- -1.15
2026-04-02FATE1.2113.3- -1.15
2026-04-06FATE1.2013.3- -1.15
2026-04-07FATE1.1613.3- -1.15
2026-04-08FATE1.1913.3- -1.15
2026-04-09FATE1.2813.3- -1.15
2026-04-10FATE1.2413.3- -1.15
2026-04-13FATE1.3213.3- -1.15
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-17FATE-0.26-0.298.69
2026-03-18FATE-0.26-0.298.69
2026-03-19FATE-0.26-0.298.69
2026-03-20FATE-0.26-0.298.69
2026-03-23FATE-0.26-0.298.69
2026-03-24FATE-0.26-0.298.69
2026-03-25FATE-0.26-0.298.46
2026-03-26FATE-0.26-0.298.46
2026-03-27FATE-0.26-0.298.46
2026-03-30FATE-0.26-0.158.46
2026-03-31FATE-0.26-0.158.46
2026-04-01FATE-0.26-0.158.46
2026-04-02FATE-0.26-0.158.46
2026-04-06FATE-0.26-0.178.46
2026-04-07FATE-0.26-0.178.46
2026-04-08FATE-0.26-0.178.46
2026-04-09FATE-0.26-0.178.46
2026-04-10FATE-0.26-0.178.46
2026-04-13FATE-0.26-0.138.95
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

-0.27

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.28

Insider Transactions

-0.26

Institutional Transactions

-0.13

Beta

2.24

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

14

Growth Score

31

Sentiment Score

48

Actual DrawDown %

98.7

Max Drawdown 5-Year %

-99.3

Target Price

4.94

P/E

Forward P/E

PEG

P/S

22.9

P/B

0.73

P/Free Cash Flow

EPS

-1.15

Average EPS Est. Cur. Y​

-1.15

EPS Next Y. (Est.)

-1.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2051.08

Relative Volume

1.42

Return on Equity vs Sector %

-93.1

Return on Equity vs Industry %

-76.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

◆ FATE Healthcare
$1.31
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
12/20
Pullback
6/25
Volume
3/15
Valuation
12/20
TP/AR
1/10
Options
8/10
RSI
57.2
Range 1M
81.7%
Sup Dist
7.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
29 /100
WEAK
Momentum
5/25
Growth
10/30
Estimates
0/20
Inst/Vol
6/15
Options
8/10
EPS Yr
1.7%
EPS NY
5.5%
52W%
47.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +277.1% upside
Quality
2/30
Valuation
16/30
Growth
7/25
Stability
6/10
LT Trend
3/5
Upside
+277.1%
Quality
14
Click a card to see score breakdown Full Analysis →
Fate Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 161
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FATE

Latest News

—
Caricamento notizie per FATE…
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading